Novo Nordisk’s Ozempic drug slows the progression of chronic kidney disease and cuts the risk of kidney failure, heart attack, stroke and death in patients with type 2 diabetes, detailed results of a long-term trial showed.
Novo Nordisk’s Ozempic drug slows the progression of chronic kidney disease and cuts the risk of kidney failure, heart attack, stroke and death in patients with type 2 diabetes, detailed results of a long-term trial showed.